Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel

The clinical success of small-molecule vascular disrupting agents (VDAs) depends on their combination with conventional therapies. Scheduling and sequencing remain key issues in the design of VDA–chemotherapy combination treatments. This study examined the antitumour activity of ZD6126, a microtubul...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinelli, M, Bonezzi, K, Riccardi, E, Kuhn, E, Frapolli, R, Zucchetti, M, Ryan, A J, Taraboletti, G, Giavazzi, R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360417/
https://www.ncbi.nlm.nih.gov/pubmed/17848949
http://dx.doi.org/10.1038/sj.bjc.6603969

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360417/
https://www.ncbi.nlm.nih.gov/pubmed/17848949
http://dx.doi.org/10.1038/sj.bjc.6603969

Ejemplares similares